SCHEMBL1901110

SCHEMBL1901110

CC(=O)Oc1ccc(-c2cc(C(=O)O)c3ccccc3n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.71
LMNA P02545 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
NPC1 O15118 2/20 0.71
ALDH1A1 P00352 2/20 0.71
HPGD P15428 2/20 0.71
RAB9A P51151 2/20 0.71
DHODH Q02127 6/20 0.70
PDE10A Q9Y233 3/20 0.69
MAPT P10636 3/20 0.67
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
ATM Q13315 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
POLB P06746 1/20 0.67
TP53 P04637 3/20 0.65
KMT2A Q03164 1/20 0.65
THRB P10828 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116026 0.88 KDM4E (0.85) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
SCHEMBL1897553 0.87 KDM4E (0.65) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
SCHEMBL31715954 0.83 LMNA (1.00) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
SCHEMBL4009073 0.83 LMNA (1.00) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
SCHEMBL2467110 0.83 DHODH (1.00) KDM4ELMNASMN1; SMN2DHODHPDE10A
SCHEMBL29536364 0.83 DHODH (1.00) KDM4ELMNASMN1; SMN2DHODHPDE10A
Cinchophen SCHEMBL25519 0.83 KDM4E (1.00) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
Cinchophen SCHEMBL29376617 0.83 KDM4E (1.00) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
Cinchophen SCHEMBL7588217 0.83 KDM4E (1.00) KDM4ELMNASMN1; SMN2NPC1ALDH1A1
SCHEMBL1899209 0.82 DHODH (0.76) KDM4ELMNASMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B KDM4E 532/4885LMNA 4766/4885SMN1; SMN2 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.